Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $1.4 million.

  • Dna X's Change in Accured Expenses fell 8559.29% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 12293.96%. This contributed to the annual value of $8.0 million for FY2024, which is 48787.66% up from last year.
  • According to the latest figures from Q3 2025, Dna X's Change in Accured Expenses is $1.4 million, which was down 8559.29% from -$1.2 million recorded in Q2 2025.
  • Over the past 5 years, Dna X's Change in Accured Expenses peaked at $9.8 million during Q3 2024, and registered a low of -$2.9 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was $315000.0 (2022), whereas its average is $467578.9.
  • The largest annual percentage gain for Dna X's Change in Accured Expenses in the last 5 years was 188641.98% (2023), contrasted with its biggest fall of 77809.52% (2023).
  • Quarter analysis of 5 years shows Dna X's Change in Accured Expenses stood at -$331000.0 in 2021, then soared by 124.47% to $81000.0 in 2022, then surged by 1886.42% to $1.6 million in 2023, then tumbled by 275.7% to -$2.8 million in 2024, then skyrocketed by 149.77% to $1.4 million in 2025.
  • Its Change in Accured Expenses was $1.4 million in Q3 2025, compared to -$1.2 million in Q2 2025 and -$218000.0 in Q1 2025.